Polypeptide preparations

A peptide and amino acid technology, applied in the direction of peptides, peptide sources, peptides, etc., can solve problems such as infection or disease

Pending Publication Date: 2021-12-21
QINGDAO MARINE BIOPHARMACEUTICAL RES INST
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, since CoViD-19 is a relatively novel variant, it will take a long time for our immune system to recognize and respond to CoViD-19. If the immune system develops into a serious infection or disease state before it is activated, it will can lead to fatal results

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Polypeptide preparations
  • Polypeptide preparations
  • Polypeptide preparations

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0034] Example 1: Peptide-HLA-I complex formation

[0035] The experiment was carried out according to the Monomer / Tetramer production protocol experimental operation flow of the easYmer HLA-A*02:01 MHC Tetramers Kit kit of the immunoware manufacturer.

[0036] 1. Weigh an appropriate amount of peptide to be tested (see Table 1), and dissolve it in dimethyl sulfoxide to 1 mM.

[0037] 2. The positive control peptide (the positive control peptide is provided by the immunoware easYmer HLA-A*02:01 MHCTetramers Kit), and the peptide to be tested is diluted to 25 μM with double distilled water.

[0038] 3. Prepare each reaction tube on ice according to the following table (see Table 2), and mix well by repeatedly pipetting with a pipette to avoid the generation of air bubbles.

[0039] 4. After sealing with the sealing tape, incubate at 18 degrees for 48 hours before use.

[0040] no size sequence no size sequence 1# 1,380 GVAPGTAVLRQW 19# 1,380 RTV...

Embodiment 2

[0044] Example 2: Detection of the Formation of Peptide-HLA-I Complex Based on Flow Cytometry

[0045] 1. Add 4 μl of peptide-HLA-I complex solution to 46 μl of dilution buffer and mix well.

[0046] 2. Add 25 μl peptide-HLA-I complex dilution to 50 μl dilution buffer and mix well.

[0047] 3. Transfer 40 μl of the dilution from step 2 to a new EP tube.

[0048] 4. Streptavidin-coated magnetic beads (6-8 μm), diluted 45 times with dilution buffer, added 20 μl to each tube, and mixed well.

[0049] 5. Incubate on a shaker at 37 degrees for 1 hour.

[0050] 6. Add 160 μl FACS solution to each tube.

[0051] 7. Centrifuge at 700g for 3 minutes and discard the supernatant.

[0052] 8. Resuspend in 200μl FACS solution, centrifuge at 700g for 3min, discard the supernatant, repeat this step, and wash twice.

[0053] 9. Dilute PE-labeled anti-human monoclonal antibody BBM.1 200 times with FACS solution.

[0054] 10. Add 50 μl of antibody diluent to each tube to resuspend, and in...

Embodiment 3

[0059] Example 3: Tetramer related:

[0060] This experiment was carried out in accordance with the Monomer / Tetramer production protocol experimental procedure of the easYmer HLA-A*02:01 MHC Tetramers Kit kit from the immunoware manufacturer.

[0061] Preparation of tetramers.

[0062] 1. Take 6 μL of the prepared 500nM polypeptide 18#, 23#, 30# and HLA-I monomer complex in a 0.2mL centrifuge tube, add 0.48μL Streptavidin-BV421 (BD; Cat#563259; 0.1mg / ml ).

[0063] 2. After mixing evenly, incubate at 4°C in the dark for 1 hour.

[0064] Isolation of Human Peripheral Blood Mononuclear Cells (PBMC)

[0065] 1. Take human venous anticoagulated whole blood (EDTA) and dilute it with an equal volume of normal saline.

[0066] 2. Add an appropriate amount of lymphocyte separation medium into a 15mL centrifuge tube, spread the diluted blood on top of the separation medium, and keep the interface between the two liquid surfaces clear.

[0067] 3. At room temperature, centrifuge ho...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

On the basis of AI-Deep-Learning technical research, activation of an MHC-I immune system is taken as a target, research is carried out aiming at CoViD-19 virus structural protein, polypeptide sequences with the length of 9-14 amino acids are predicted, the polypeptides can obviously activate the immune system of a body, and a foundation is laid for designing a safe and effective polypeptide vaccine.

Description

technical field [0001] The present invention relates to biological products, especially polypeptide products. Background technique [0002] Activated T lymphocytes play an important role in anti-tumor, anti-infection, and autoimmune diseases. The activation of T cells requires two different signals. The first signal comes from the interaction between TCR (Tcell receptor, T cell receptor) and antigen peptide-MHC (major histocompatibility complex, major histocompatibility complex) complex, triggering a series of antigen-specific T cell responses, including intracellular The activation of two signaling pathways, calcineurin, MAPK and NF-κB, leads to downstream molecular events to initiate the expression of various genes, including IL-2, IL-2L receptor (CD25), CD69 and CD154, etc. The second signal comes from the co-stimulatory signal generated by the combination of B7 family molecules on APC (antigen presenting cells) and its ligand CD28 family molecules on T cells, such as t...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): C07K14/165A61K39/215A61K45/06A61P37/04A61P31/12A61P31/14A61P31/16A61P31/20A61P31/22A61P31/18G01N33/569
CPCC07K14/005A61K39/12A61K45/06A61P37/04A61P31/12A61P31/14A61P31/20A61P31/22A61P31/18A61P31/16G01N33/56983C12N2770/20022C12N2770/20034G01N2333/165
Inventor 杨金波申載敏刘珊冉祥宋巧玲郑英柱姚丹杨萌琳赵晨阳
Owner QINGDAO MARINE BIOPHARMACEUTICAL RES INST
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap